EMA/11655/2021

European Medicines Agency decision

P/0067/2021

of 18 February 2021

on the acceptance of a modification of an agreed paediatric investigation plan for ozanimod hydrochloride (Zeposia), (EMEA-001710-PIP04-17-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0067/2021

of 18 February 2021

on the acceptance of a modification of an agreed paediatric investigation plan for ozanimod hydrochloride (Zeposia), (EMEA-001710-PIP04-17-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0050/2019 issued on 29 January 2019,

Having regard to the application submitted by Celgene Europe B.V. on 22 October 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 January 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for ozanimod hydrochloride (Zeposia), capsule, hard, age-appropriate oral solid dosage form, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/0198/2015 issued on 4 September 2015, including subsequent modifications thereof.

Article 3

This decision is addressed to Celgene Europe B.V., Winthontlaan 6n, 3526 KV – Utrecht, The Netherlands.

EMA/PDCO/593992/2020
Amsterdam, 29 January 2021

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001710-PIP04-17-M02

Scope of the application

Active substance(s):

Ozanimod (hydrochloride)

Invented name:

Zeposia

Condition(s):

Treatment of Crohn's disease

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Capsule, hard

Age-appropriate oral solid dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Celgene Europe B.V.

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Celgene Europe B.V. submitted to the European Medicines Agency on 22 October 2020 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0050/2019 issued on 29 January 2019.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 1 December 2020.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of Crohn's disease

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- capsule, hard, age-appropriate oral solid dosage form, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of Crohn's disease

2.1.1. Indication(s) targeted by the PIP

Treatment of moderate to severe active Crohn's disease

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Capsule, hard

Age-appropriate oral solid dosage form

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of an age-appropriate oral solid dosage form.
Non-clinical studies	1	**Study 2** 33-Day oral immunotoxicity study in juvenile Sprague-Dawley rats.
Clinical studies	1	**Study 3 (RPC01-3201)** study deleted as part of modification EMEA-001710-PIP04-17-M02 **Study 4 (RPC01-3202)** study deleted as part of modification EMEA-001710-PIP04-17-M02

		Study 5 (RPC01-3203) study deleted as part of modification EMEA-001710-PIP04-17-M02 **Study 6 (RPC01-3204)** study deleted as part of modification EMEA-001710-PIP04-17-M02 **Study 7 (CD-PED-PK)** study deleted as part of modification EMEA-001710-PIP04-17-M02 **Study 8 (CD-PED-PH3)** study deleted as part of modification EMEA-001710-PIP04-17-M02 **Study 10 (CD – PED – PH2/PH3)** new study added as part of modification EMEA-001710-PIP04-17-M02 Randomized, double-blind study to estimate the efficacy, safety and tolerability, and pharmacokinetics (PK)/pharmacodynamics (PD) of two doses of oral ozanimod in paediatric patients from 2 years to less than 18 years with moderately to severely active Crohn's disease (CD).
Extrapolation, modelling and simulation studies	3	**Study 9** Modelling and simulation study, to evaluate use of ozanimod in children from 2 years to less than 18 years of age with moderately to severely active Crohn's disease (CD). **Study 11** new study added as part of modification EMEA-001710-PIP04-17-M02 Modelling and simulation study, to characterize the PK/PD and exposure response (E-R) efficacy relationships of ozanimod in paediatric patients from 2 years to less than 18 years of age with moderately to severely active Crohn's disease (CD). **Study 12** new study added as part of modification EMEA-001710-PIP04-17-M02 Integrated analysis of Population PK, Population PK/PD and Exposure-Response Modelling Results of ozanimod for treatment of paediatric patients with CD.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By August 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of multiple sclerosis

Authorised indication(s):

- Zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.

Authorised pharmaceutical form(s):

Hard capsules

Authorised route(s) of administration:

Oral use